CRP

crp

Episode 213: Questions that lead to questions and then more questions - Part II

In episode 213, James and Mike continue on their merry quest of answering the world’s problems. We discuss CRP, ibuprofen for pain, zoster vaccines, thiazides and risk calculators. The questions are answered so well that at the very end Mike and James also solve world hunger and the Middle East crisis.

Show notes 

1) CRP measurements Read more »

Episode 74: Vitamin A, B, C, NOT D, and E - not all letters are created equal

In episode 74, Mike (Bert) and James (Ernie), along with Tina (Betty Lou) continue their stroll down medical Sesame Street and take a look at the evidence behind Vitamins (Letters) A,B,C, and E. Lo and behold, they find that not all letters are created equal and some are even quite bad. Read more »

Episode 54: CRP - An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice- Part III

Episode 54 finishes off the whole issue of CRP measurement by looking at the evidence we have about what happens to patients when they take drugs that lower CRP - glitazones, COX-2s, fibrates, vitamin E, niacin, ezetimibe, and statins. Other than statins and maybe niacin, it doesn't look good - in contrast to Mike and James of course that is. Read more »

Episode 53: CRP - An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice- Part II

Episode 53 continues where we left with the whole CRP measurement or no measurement discussion. James and Mike start with the Reynolds Risk Score and show how even at the extremes of CRP, absolute risks only change by around +/- 2% or so. Read more »

Episode 52: CRP - An important part of a Comprehensive Risk Profile or a Completely Ridiculous Practice

Episode 52 goes back in time to look in more detail at what we talked about in episode 30; the whole issue of CRP measurement. Mike and James start at the "large" issue of intra-subject variability, then focus on the "small" impact CRP has on absolute risk assessment, and briefly discuss how "accurate" risk assessments are in the first place. Read more »

Episode 30: A New Far-Out Trial: Welcome to Jupiter

The topic for our 30th episode is stolen from the headlines. We look at the much publicized Jupiter trial of C-Reactive Protein (CRP) and the use of a statin. We review the details, strengths and weakness of the trial. From there we look at related questions of risk assessment with CRP, reducing CRP and the uncertainty in the lipid hypothesis. Read more »

Syndicate content